首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗開發業務受託機關

市場調查報告書

商品編碼

1968009

全球臨床前CRO市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Preclinical CRO Market Size, Share, Trends & Growth Analysis Report 2026-2034

出版日期: 2026年02月05日 | 出版商:

Value Market Research | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計臨床前 CRO 市場將從 2025 年的 68.3 億美元成長到 2034 年的 140.2 億美元，2026 年至 2034 年的複合年成長率為 8.31%。

受製藥和生物技術領域研發活動日益活躍的推動，全球臨床前CRO市場正迅速擴張。企業將臨床前試驗外包，以降低營運成本並縮短藥物研發週期。對包括生物製藥和基因療法在內的新型治療方法的投資不斷增加，也推動了對專業研究服務的需求。隨著藥物研發管線日趨複雜，對專業合約研究組織（CRO）的需求進一步成長。

試管內測試、動物模型和數據分析方面的技術進步正在提高研究效率。隨著安全性和有效性測試的監管要求日益嚴格，對經驗豐富的合約研究組織（CRO）合作夥伴的依賴也越來越強。新興生物技術Start-Ups傾向於外包，以便專注於其核心業務。此外，學術機構與CRO之間合作的加強也促進了創新和研究能力的提升。

展望未來，全球研發投入的成長可望推動市場發展。人工智慧藥物發現和預測毒理學等先進技術的引入預計將拓展服務範圍。亞太地區可望憑藉成本優勢和不斷完善的研發基礎設施，成為關鍵成長區域。持續創新和策略夥伴關係有望支撐市場的長期擴張。

區域分析
北美市場分析、洞察與預測
- 美國
- 加拿大
- 墨西哥
歐洲市場分析、洞察與預測
- 英國
- 法國
- 德國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太市場分析、洞察與預測
- 印度
- 日本
- 韓國
- 澳洲
- 東南亞
- 其他亞太國家
拉丁美洲市場分析、洞察與預測
- 巴西
- 阿根廷
- 秘魯
- 智利
- 其他拉丁美洲國家
中東和非洲市場分析、洞察與預測
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 其他中東和非洲國家

第8章競爭情勢

最新趨勢
公司分類
供應鏈和銷售管道合作夥伴（根據現有資訊）
市場佔有率和市場定位分析（基於現有資訊）
供應商情況（基於現有資訊）
策略規劃

第9章：公司簡介

主要公司的市佔率分析
公司簡介
- WuXi AppTec Inc
- Labcorp（Laboratory Corporation Of America Holdings）
- Eurofins Scientific SE
- Medpace Holdings Inc
- Charles River Laboratories International Inc
- Intertek Group Plc
- PPD（Thermo Fisher Scientific Inc.）
- ICON Plc（Formerly Including PRA Health Sciences）
- Covance（LabCorp）
- Crown Bioscience

簡介目錄

Product Code: VMR112110008

The Preclinical CRO Market size is expected to reach USD 14.02 Billion in 2034 from USD 6.83 Billion (2025) growing at a CAGR of 8.31% during 2026-2034.

The Global Preclinical CRO Market is expanding rapidly due to increasing pharmaceutical and biotechnology research activities. Companies are outsourcing preclinical studies to reduce operational costs and accelerate drug development timelines. Rising investments in novel therapeutics, including biologics and gene therapies, are fueling demand for specialized research services. Growing complexity of drug pipelines is further strengthening the need for expert contract research organizations.

Technological advancements in in vitro testing, animal models, and data analytics are enhancing research efficiency. Regulatory requirements for safety and efficacy testing are becoming more stringent, driving reliance on experienced CRO partners. Emerging biotech startups prefer outsourcing to focus on core competencies. Additionally, increased collaboration between academic institutions and CROs is boosting innovation and research capabilities.

Looking ahead, the market is expected to benefit from rising R&D expenditure globally. Adoption of advanced technologies such as AI-driven drug discovery and predictive toxicology will likely expand service offerings. Asia-Pacific is anticipated to emerge as a significant growth region due to cost advantages and expanding research infrastructure. Continuous innovation and strategic partnerships are expected to sustain long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service

Bioanalysis and DMPK studies
Toxicology Testing
Compound Management
Process R&D
Chemistry
Safety Pharmacology
Others

By Model Type

Patient Derived Organoid (PDO) Model
Patient Derived Xenograft Model

By End-use

Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

COMPANIES PROFILED

WuXi AppTec Inc, Labcorp Laboratory Corporation of America Holdings, Eurofins Scientific SE, Medpace Holdings Inc, Charles River Laboratories International Inc, Intertek Group plc, PPD Thermo Fisher Scientific Inc, ICON plc formerly including PRA Health Sciences, Covance LabCorp, Crown Bioscience
We can customise the report as per your requirements.

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL PRECLINICAL CRO MARKET: BY SERVICE 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Service
4.2. Bioanalysis and DMPK studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Toxicology Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Compound Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Process R&D Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Chemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. Safety Pharmacology Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PRECLINICAL CRO MARKET: BY MODEL TYPE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Model Type
5.2. Patient Derived Organoid (PDO) Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Patient Derived Xenograft Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PRECLINICAL CRO MARKET: BY END-USE 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast End-use
6.2. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Government and Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Medical Device Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PRECLINICAL CRO MARKET: BY REGION 2022-2034(USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Service
- 7.2.2 By Model Type
- 7.2.3 By End-use
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Service
- 7.3.2 By Model Type
- 7.3.3 By End-use
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Service
- 7.4.2 By Model Type
- 7.4.3 By End-use
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Service
- 7.5.2 By Model Type
- 7.5.3 By End-use
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Service
- 7.6.2 By Model Type
- 7.6.3 By End-use
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PRECLINICAL CRO INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 WuXi AppTec Inc
- 9.2.2 Labcorp (Laboratory Corporation Of America Holdings)
- 9.2.3 Eurofins Scientific SE
- 9.2.4 Medpace Holdings Inc
- 9.2.5 Charles River Laboratories International Inc
- 9.2.6 Intertek Group Plc
- 9.2.7 PPD (Thermo Fisher Scientific Inc.)
- 9.2.8 ICON Plc (Formerly Including PRA Health Sciences)
- 9.2.9 Covance (LabCorp)
- 9.2.10 Crown Bioscience